Introduction {#Sec1}
============

Methicillin-susceptible *Staphylococcus aureus* (MSSA) is one of the most common causes of complicated skin and soft tissue infection (cSSTI) \[[@CR1]\]. Among deeper cSSTI and those located in the lower limb of diabetic patients, Gram-negative bacilli, *Escherichia coli, Klebsiella pneumoniae*, and *Proteus* species, are also commonly isolated \[[@CR1], [@CR2]\]. Based on this epidemiology, intravenous cefazolin has often been used to treat cSSTI for organisms proven susceptible in the hospital settings. However, dosing recommendations vary based on source and organism. Current US labeling for cefazolin includes a variety of dosing regimens as low as 250 mg every 8 h (q8h) up to 2 g q8h \[[@CR3]\].

Susceptibility breakpoints also vary for cefazolin; the U.S. Food and Drug Administration (FDA), the European Committee on Antimicrobial Susceptibility Testing (EUCAST), or the Clinical Laboratory Standards Institute (CLSI) breakpoints have not taken cefazolin tissue exposure into account when selecting susceptibility thresholds. The FDA susceptibility breakpoint for cefazolin against *S. aureus* has remained ≤16 mg/L for decades \[[@CR3]\], while cefazolin minimum concentration at which 50% (MIC~50~) and 90% (MIC~90~) of the isolates were inhibited against MSSA was recently reported as 0.5 mg/L and 1 mg/L, respectively \[[@CR4]\]. EUCAST has not published a cefazolin susceptibility breakpoint for Enterobacteriaceae and relies on the cefoxitin disc test for determining universal susceptibility to first-generation cephalosporins. The CLSI uses a similar definition for *S. aureus*, and more recently has modified its susceptibility breakpoint for Enterobacteriaceae twice since 2010. This was prompted by publications reporting treatment failures from cephalosporins in infections caused by Enterobacteriaceae that were previously categorized as susceptible \[[@CR5]--[@CR7]\]. Initially, it was lowered from ≤8 mg/L to ≤1 mg/L in 2010 with the advent of in vitro susceptibility, pharmacodynamic, and clinical outcome data. It was then readjusted to ≤2 mg/L in 2011 with the recommendation of a 2 g q8h dosing regimen, so that it could still be a viable option for Enterobacteriaceae without intrinsic chromosomal cephalosporinases \[[@CR7]\].

In an effort to quantify drug concentrations in the interstitial fluid (ISF) of tissue to determine if appropriate pharmacodynamic targets are achieved at the site of infection, our group previously reported ISF exposure of cefazolin in seven chronic lower extremity wound infections utilizing in vivo microdialysis techniques \[[@CR8], [@CR9]\]. The non-compartmental pharmacokinetic analysis from the study showed the mean and median tissue penetration ratios \[ISF/serum free drug area under the curve (*f*AUC)\] of 1.06 and 0.88 with a wide range of 0.19--1.68. The percent of the dosing interval that free drug concentrations remained above the MIC (%*f*T \> MIC) in the sampled ISF was 100% at an MIC of 1 mg/L for five out of six patients who received 1 g q8h dose during the study.

In this study, we aimed to describe the population pharmacokinetics of cefazolin in both serum and ISF utilizing the data from the aforementioned study \[[@CR8]\]. We used this model to simulate the potential variability in penetration into ISF of tissue and to compare the likelihood of achieving targeted drug exposure (i.e., *f*T \> MIC) in the ISF compartment between 1 g versus 2 g q8h regimens.

Methods {#Sec2}
=======

Patient Population and Setting {#Sec3}
------------------------------

Included patients were those from the aforementioned in vivo microdialysis study, which was an open-label pharmacokinetic study at Hartford Hospital, Hartford, CT, USA \[[@CR8]\]. Inclusion criteria were hospitalized adult patients (age ≥18 years) with lower extremity wound infections requiring surgical debridement and defined as mild or moderate by the Infectious Diseases Society of America or as grade 2 or 3 by the International Consensus on the Diabetic Foot \[[@CR10]\]. Patients with hypersensitivity to anesthetics (lidocaine or lidocaine derivatives), pregnancy or breastfeeding, no palpable pedal pulses, likelihood to require multiple procedures during the study, participation in another study of an investigational drug or device within the preceding 30 days, and patients with renal dysfunction, defined as an estimated creatinine clearance (CrCl) less than 50 mL/min, were excluded. The analysis in this article is based on a previously conducted study and does not involve any new studies with human or animal subjects performed by any of the authors.

Drug Administration {#Sec4}
-------------------

All patients received intravenous cefazolin over 30 or 60 min for their lower extremity wound infections via a peripheral catheter placed in the arm or a peripherally inserted central catheter (PICC). All patients included in this analysis received 1 g q8h dosing.

Sampling and Determination of Cefazolin Concentrations {#Sec5}
------------------------------------------------------

Venous blood samples (7--9 per patient) were collected at various time points from a peripheral intravenous catheter or PICC after a minimum of four doses (i.e., steady state). Sampling time points included immediately prior to and after the infusion, several points hourly after the infusion, and then just prior to the next dose. Dialysate samples of \~120 µL were obtained from the microdialysis catheters at each of the corresponding blood sample time points. Microdialysis catheters were calibrated for each patient after sampling by using the in vivo retrodialysis technique \[[@CR11]\]. Cefazolin concentrations in serum and ISF were quantified by a validated high-performance liquid chromatography assay \[[@CR12]\].

Population Pharmacokinetics {#Sec6}
---------------------------

Cefazolin serum and ISF concentrations were co-modeled by the non-parametric adaptive grid (NPAG) with adaptive gamma algorithm available in the Pmetrics package for R (LAPK, Los Angeles, CA, USA) \[[@CR13]\]. A total of 53 serum and 53 ISF concentrations from six patients were used, and individual concentrations were weighted by the reciprocal of assay variance multiplied by gamma. Weighting based on interday assay variance was employed using a plot of the assay standard deviation (SD) versus measured cefazolin concentrations, which was best described by the equations: SD~serum~ = γ(0.0071 + 0.0449 × *C*1) and SD~ISF~ = γ(0.0002 + 0.0560 × *C*2), where *C*1 and *C*2 are cefazolin concentrations in serum and ISF, respectively, and γ was identified as 3.76. Mean values were used as the measure of central tendency for population parameter estimates. Bayesian estimates were obtained for each patient using the population-of-one utility within Pmetrics.

Both two- and three-compartment models were explored, with one of the compartments being the sampled ISF. Multiple models were evaluated and discriminated employing the Akaike Information Criterion (AIC) \[[@CR14]\], which is a function of the likelihood of the model, penalized by the number of parameters in the model, bias, imprecision, and by visual inspection of the observed versus predictive concentration plots. The mean weighted error was used as the estimate of bias. The bias-adjusted mean weighted squared error was employed as the estimate of imprecision.

Linear regression (Sigma Plot Version 12.5, Systat, Chicago, IL, USA) was used to characterize the relationship between pharmacokinetic parameters (CL, clearance from central compartment; *V*~c~, volume of central compartment and *V*~ISF~, volume of sampled ISF compartment) and patient covariates (CrCl calculated by Cockcroft--Gault equation \[[@CR15], [@CR16]\], TBW, total body weight and BMI, body mass index). Covariates that were statistically significantly correlated were then incorporated back into the population model and tested for model superiority.

Monte Carlo Simulations {#Sec7}
-----------------------

A 5,000 patient semi-parametric Monte Carlo Simulation (Pmetrics) \[[@CR13]\] was conducted to simulate steady-state concentrations of cefazolin 1 g and 2 g in both serum and ISF. Pmetrics' semi-parametric simulator uses the non‐parametric "support points" from the final population model, each a vector of one value for each parameter in the model and the associated probability of that set of parameter values, to serve as the mean of one multivariate normal distribution. The weight of each multivariate distribution is equal to the probability of the point. The overall population covariance matrix is divided by the number of support points and applied to each distribution for sampling. Cefazolin concentrations in serum and tissue for seven doses of each regimen were simulated every 15 min after the last dose. A fraction unbound of 15% (i.e., 85% protein binding) was applied to correct all serum concentrations to free drug concentrations. This fraction unbound estimate was consistent across the six patients, as well as within each patient across the dosing interval \[[@CR8]\]. ISF concentrations were assumed to be unbound during calculation of AUC and *f*T \> MIC in ISF. The AUC for a dosing interval of 8 h (AUC~0--8~) at steady state was estimated in serum and ISF after simulation to calculate the penetration into ISF as AUC~ISF~/*f*AUC~serum~. The probability of target attainment (PTA) was calculated using a priori pharmacodynamic targets defined as 30%, 50%, and 100% *f*T \> MIC in serum and ISF.

Results {#Sec8}
=======

Patient Characteristics {#Sec9}
-----------------------

A total of six patients were included in this analysis. Five out of six patients were male and their age ranged from 35 to 83 years with a mean ± SD of 55 ± 17 years (Table [1](#Tab1){ref-type="table"}). Five out of six patients had diabetes (one with type I, four patients with type II). One patient did not have diabetes but had significant neuropathy, which contributed to the foot infection. None of the six patients had a history of peripheral vascular disease, and all had pedal pulses from +1 to +3 at the time of sampling. Surgical interventions involved were amputation or debridement of the infected tissue and/or bone. Sampling occurred after the surgical intervention for five out of the six patients except in one patient, which occurred a day prior to surgery.Table 1Patient characteristicsSubjectSexAge (years)Weight (kg)Height (cm)IBW (kg)BMI (kg/m^2^)CrCl (mL/min)HbA1c (%)PEDIS gradeClinical diagnosisLocation of infectious foci1M35731858021.29012.33Gangrene, OMPhalanges2F351071837332.021513.53Chronic ulcer, OMMetatarsal head3M551021908428.01425.02Open necrotic ulcerPlantar4M83751807523.085N/AN/AAbscess, OMMetatarsal and phalanges5M70961837828.7697.83OMPhalanges6M531201837537.01417.73AbscessMetatarsophalangeal jointMean55961847828.31249.3SD1717345.3493.2CrCl calculated by Cockcroft--Gault equation. PEDIS grade as defined by the International Consensus on the Diabetic Foot \[[@CR10]\] and calculated for the five patients with diabetes*BMI* Body mass index, *CrCl* creatinine clearance, *F* female, *HbA1c* glycosylated hemoglobin, *IBW* ideal body weight, *M* male, *N/A* data not available, *OM* osteomyelitis, *PEDIS* perfusion, extent/size, depth/tissue loss, infection and sensation, *SD* standard deviation

Population Pharmacokinetics {#Sec10}
---------------------------

A three-compartment base model fit the data better than a two-compartment model based on our discrimination criteria. Although linear regression identified CrCl as the only patient covariate that was significantly correlated with CL (*r*^2^ = 0.822, *P* = 0.005) and no patient covariates were significantly correlated with *V*~c~ or *V*~ISF~, incorporation of CrCl back into the base model did not improve the AIC. Therefore, the simpler non-covariate three-compartment model was selected. The final model AIC and log-likelihood were 453.3 and −218.8, respectively. Final population pharmacokinetic parameters obtained from the analysis are listed in Table [2](#Tab2){ref-type="table"}.Table 2Final parameter estimates from the population pharmacokinetic modelParameterCL (L/h)*V* ~c~ (L)*K* ~12~ (h^−1^)*K* ~21~ (h^−1^)*K* ~13~ (h^−1^)*K* ~31~ (h^−1^)*V* ~ISF~ (L)Mean3.88.61.64.01.42.036.6SD2.16.41.61.61.31.517.9%CV55.274.6103.740.994.272.248.8Median2.86.52.15.00.90.941.0*CL* Clearance from central compartment, *K* ~*12*~ transfer rate constant from central to peripheral compartment, *K* ~*13*~ transfer rate constant from central to the sampled interstitial fluid of tissue compartment, *K* ~*21*~ transfer rate constant from peripheral to central compartments, *K* ~*31*~ transfer rate constant from the sampled interstitial fluid of tissue compartment to central compartment, *SD* standard deviation, %*CV* coefficient of variation, *V* ~*c*~ volume of the central compartment, *V* ~*ISF*~ volume of the sampled interstitial fluid of tissue compartment

Figure [1](#Fig1){ref-type="fig"} demonstrates the observed versus (Fig. [1](#Fig1){ref-type="fig"}a) population predicted and (Fig. [1](#Fig1){ref-type="fig"}b) individual predicted maximum posterior (MAP) concentrations in serum. The population predicted estimates were reasonable for a patient population with variable pharmacokinetics with *r*^2^, bias, and imprecision values of 0.64, 12.7, and 920, respectively (Fig. [1](#Fig1){ref-type="fig"}a). MAP Bayesian concentration plot in serum was excellent with *r*^2^, bias, imprecision values of 0.98, −0.373, and 7.6, respectively (Fig. [1](#Fig1){ref-type="fig"}b). In ISF, the observed versus population predicted *r*^2^, bias, and imprecision were 0.198, 20.1, and 1,394 (Fig. [2](#Fig2){ref-type="fig"}a), and the corresponding values for the observed versus individual MAP Bayesian plot were 0.887, −1.17, and 21.3, respectively (Fig. [2](#Fig2){ref-type="fig"}b).Fig. 1Observed versus (**a**) population predicted and (**b**) individual predicted maximum posterior Bayesian cefazolin concentrations (mg/L) in serum. *CI* Confidence interval, *Inter* InterceptFig. 2Observed versus (**a**) population predicted and (**b**) individual predicted maximum posterior Bayesian cefazolin concentrations (mg/L) in interstitial fluid of tissue. *CI* Confidence interval, *Inter* Intercept

The mean ± SD and median penetration ratios for the six included patients based on their individual Bayesian parameter estimates were 0.90 ± 0.48 and 0.72, respectively.

Monte Carlo Simulation {#Sec11}
----------------------

Parameter estimates from the Pmetrics semi-parametric simulator recapitulated the mean, SD, and median estimates of the original model. The mean ± SD and median penetration ratios for 5,000 simulated patients were 1.36 ± 4.57 and 0.80, respectively. The 5th and 95th percentiles for simulated penetration into ISF were 0.15 and 2.74, respectively. PTA results for serum and ISF exposures of 30%, 50%, and 100% *f*T \> MIC are provided in Table [3](#Tab3){ref-type="table"}.Table 3Probability of achieving pharmacodynamic exposure thresholds in serum (a) and interstitial fluid of tissue (b) for cefazolin 1 g and 2 g q8h dosing regimens from 5,000 patient Monte Carlo simulationMIC (mg/L)1 g q8h2 g q8h30% *f*T \> MIC50% *f*T \> MIC100% *f*T \> MIC30% *f*T \> MIC50% *f*T \> MIC100% *f*T \> MIC(a) Serum 0.1251.000.990.961.000.990.96 0.250.990.990.931.000.990.96 0.50.990.980.840.990.990.93 10.990.970.660.990.980.84 20.980.790.410.990.970.66 40.770.610.080.980.790.41 80.330.090.010.770.610.08 160.030.010.000.340.090.01(b) Interstitial fluid of tissue 0.1250.990.980.930.990.990.95 0.250.990.970.890.990.980.93 0.50.980.960.770.990.970.89 10.960.910.580.980.960.77 20.870.710.390.960.910.58 40.580.450.200.870.710.39 80.290.180.080.580.450.20 160.100.070.030.290.180.08*fT* \> *MIC* Free time above MIC, *q8h* every 8 h

Discussion {#Sec12}
==========

The previously published cefazolin in vivo microdialysis study by our group evaluated ISF concentrations of intravenously administered cefazolin for the treatment of cSSTI \[[@CR8]\]. The primary goal of the current study was to describe the population pharmacokinetics using the same serum and ISF concentration data to assess variability in ISF penetration and the likelihood of achieving *f*T \> MIC in the ISF compartment between 1 g and 2 g q8h regimens.

A three-compartment model best described the pharmacokinetics of cefazolin in our population with normal renal function. The resultant CL of 3.78 ± 2.09 L/h from our population pharmacokinetic model was concordant with the values from the non-compartmental analysis, 3.72 ± 2.16 L/h \[[@CR8]\]. Cefazolin CL in this population was also similar to most other reported values. van Kralingen and colleagues \[[@CR17]\] have reported CL of 4.2 ± 0.1 L/h in patients with average ± SD age of 44 ± 11 years, TBW of 151 ± 35 kg, and BMI of 51 ± 10 kg/m^2^ after a single prophylactic dose of 2 g prior to bariatric surgery. They also observed CL had a significant negative correlation with age, but not with body weight. Douglas and colleagues \[[@CR18]\] reported median CL of 3.01 L/h (interquartile range: 1.73--3.94 L/h) after a single 2 g cefazolin in patients undergoing abdominal aortic aneurysm open repair surgery. A tissue penetration study of cefazolin in morbidly obese versus non-obese patients reported a CL of approximately 23 L/h \[[@CR19]\]; however, this estimate was based on unbound cefazolin concentrations and is therefore not directly comparable. Nonetheless, this unbound CL estimate is feasible because cefazolin is highly protein bound; protein binding in our six patients was 85%.

The observed mean ± SD and median penetration ratios from our six patients using their individual Bayesian parameter estimates were 0.90 ± 0.48 and 0.72 (range 0.61--1.87), respectively; these values were similar to the original observed penetration ratios based on trapezoidal rule: 1.21 ± 0.67 and 0.90 (range 0.7--2.68), respectively \[[@CR8]\]. The Monte Carlo simulation incorporates variability between patients in the pharmacokinetic estimates, and as a result, the mean ± SD and median simulated penetration ratios were 1.36 ± 4.57 and 0.80, respectively. These penetration ratio are comparable with the values observed by Brill and colleagues \[[@CR19]\] who compared population pharmacokinetics of surgical prophylactic dose of cefazolin 2 g in both morbidly obese (BMI 47 ± 6 kg/m^2^) and non-obese (BMI 28 ± 3 kg/m^2^) patients using in vivo microdialysis. Their observed *f*AUC~ISF~/AUC~serum~ was 0.70 (range 0.68--0.83) in morbidly obese and 1.02 (range 0.85--1.41) in non-obese patients. The aforementioned study by Douglas and colleagues \[[@CR18]\] reported 85% penetration (range 78--106%). Taken collectively, these data consistently suggest that there is the potential for a wide range in the estimate for cefazolin penetration into ISF, which may unpredictably be greater than or less than exposures in serum.

While penetration ratio was calculated to display the relative exposure of cefazolin in ISF of tissue versus in serum, the pharmacodynamic target of interest for the efficacy of cefazolin in ISF remains *f*T \> MIC \[[@CR20]--[@CR22]\]. Although the cefazolin target *f*T \> MIC in ISF needed for efficacy against MSSA and Enterobacteriaceae are unknown, 30% for MSSA \[[@CR22]--[@CR24]\] and 50% for Enterobacteriaceae \[[@CR22], [@CR25], [@CR26]\] were employed as these are targets required in blood. A target of 100% *f*T \> MIC was also included for comparison. Consistent with current breakpoints, where applicable, PTAs for cefazolin 1 g q8h in serum were high at MICs of 1 mg/L and 2 mg/L (Table [3](#Tab3){ref-type="table"}a). However, analysis of exposure probabilities in tissue revealed much lower PTA results. At the MIC~90~ for MSSA of 1 mg/L, the PTA for a 1 g q8h dose in ISF was 96% using the 30% *f*T \> MIC target (Table [3](#Tab3){ref-type="table"}b). At an MIC of 2 mg/L, the current-susceptible breakpoint for Enterobacteriaceae, a 1 g q8h regimen obtained a PTA of 71% for 50% *f*T \> MIC (Table [3](#Tab3){ref-type="table"}b), but a 2 g q8h dosing regimen increased the PTA to 91% for the same target (Table [3](#Tab3){ref-type="table"}b). PTAs for 50% *f*T \> MIC in tissue from our study for the 2 g dose are comparable with PTAs reported by Brill and colleagues \[[@CR19]\]: 96% and 91% (Table [3](#Tab3){ref-type="table"}b) versus 100% and 96% at MIC of 1 mg/L and 2 mg/L, respectively.

The primary limitation of our study is its small sample size. Only six patients, all with normal renal function, were included in the final model. Despite the knowledge of correlation between cefazolin CL and renal dysfunction, the small number of patients with normal renal function in our study made it challenging to improve the model by adding this covariate. Additionally, while morbid obesity can be an important factor in determining cefazolin pharmacokinetics \[[@CR19]\], our small sample size did not allow us to use weight as a covariate and future studies are needed to further define optimal cefazolin dosing in this population. Nonetheless, this is the first study to address variability in cefazolin penetration among patients with chronic wound infections. Our results are also consistent with the current recommended dosing regimen for treatment of Enterobacteriaceae based on the CLSI breakpoint (i.e., 2 g q8h), as well as the dosage typically utilized for *S. aureus* skin and soft tissue infections (i.e., 1 g q8h).

Conclusion {#Sec13}
==========

Cefazolin penetration into the ISF of a lower limb infection varied across this simulated patient population. Cefazolin 1 g q8h *f*T \> MIC exposures in serum were high at MICs of 1 mg/L and 2 mg/L. Based on the tissue ISF exposure in this mixed obese and non-obese population with normal renal function, 1 g q8h dose regimen should be sufficient to achieve 30% *f*T \> MIC target against most MSSA causing cSSTI. However, for Enterobacteriaceae with MIC of 2 mg/L, PTAs for the established 50% *f*T \> MIC target were not optimal with 1 g q8h dose. At least 2 g q8h dose is required to achieve PTA of ≥80% when treating cSSTI caused by susceptible Enterobacteriaceae (MIC ≤ 2 mg/L).
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